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We thank all the physicians who submitted letters to the editor.  However, some of 
the information in these letters are misrepresentations of our study findings (1). All 
the letter writers either stated that 10 completed the protocol or only include 10 of 
the subjects in their discussion.  Twelve women completed the protocol.  Two 
women, one in each group, discontinued early for symptoms, which is an outcome. 
Dr. Delgado and colleagues note that the findings are too small for statistical 
significance yet claim that these results are consistent with their previous findings. 
When a study is this small, one cannot state the efficacy findings are consistent 
with anything. For example, our study had 4 women at 56 days or greater, one 
received progesterone and three received placebo. The continuation rate at two 
weeks post treatment was 0/1 (0%) in the progesterone group and 1/3 (33%) in the 
placebo group. According to their logic, these results suggest that continuing 
pregnancy rates are higher with placebo than progesterone at 56 days or greater, 
which is inconsistent with the partial report from Delgado and colleagues that 
suggested a higher continuing pregnancy rate with advancing gestational age (2). 
We cannot pick and choose which data “validate” our bias and ignore the rest. 
In all, the prior large “case series” from Delgado and colleagues selectively reports 
outcomes in an unethical and invalid scientific manner (2). Their partial report of 
approximately 750 women who supposedly received some type of progesterone 
treatment after using mifepristone did not include outcomes of all treated patients, 
did not report gestational age in approximately 25% of women, and did not report 
any outcomes for the approximately 50% of women for whom the pregnancy did 
not continue. Given the omission of this basic information, what other information is
missing and how much of the report is even true? Valid scientific studies ensure 
adequate safety of subjects and report all outcomes; anything less is not science. 
Even completely reported case series represent the lowest level of research and 
cannot be used to justify treatment protocols.
Dr. Butterfield-Kalk opines on a theoretical improvement for a yet unproven 
treatment, recommending progesterone 400 mg twice daily for 5 days rather than 
the 3 days used in our study and the “case series” of Delgado and colleagues.  This 
comment underscores the fact that no progesterone regimen has been proven to 
have any effect on continuing pregnancy rates after mifepristone ingestion for 
medical abortion. In other words, we have no evidence that using progesterone has 
any greater effect than doing nothing.
Dr. Valley surmises that one of the women who called an ambulance and went to 
the emergency room because of hemorrhage was actually fine, so her outcome is 
unimportant. We disagree. An emergency room visit, which is very infrequent with 
medical abortion care (3), is a safety outcome that clinicians and patients would 
find important.
Unfortunately, legislators in some states have passed laws mandating counseling 
regarding stopping medical abortion despite a lack of proven benefit with 
progesterone treatment. Instead, for the rare person who no longer desires to 
continue with medical abortion, we should be clear about the risks and benefits of 
not taking misoprostol. Providing progesterone treatment should occur only in the 
context of an approved study protocol with appropriate oversight, in an honest 
attempt to determine efficacy and safety.  Laws that require counseling about 
unproven treatments and encourage women to participate in an unmonitored 
experiment are, quite simply, bad medicine. 
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